髓过氧化物酶水平与急性冠脉综合征不良事件发生率的关系

Clinical implication of myeloperoxidase in the risk for subsequent cardiovascular events of acute coronary syndromes

目的通过对血清促炎症介质髓过氧化物酶(MPO)在急性冠脉综合征(ACS)患者中的测定,探讨其在ACS危险分层的临床意义。方法病人分为两组:ACS组(STEMI患者32例,UAP/NSTEMI组患者38例)和对照组(SAP患者20例)。用分光光度比色法检测血清MPO活性。随访各组于30、90 d的后继心血管事件发生率,并对结果进行统计学分析。结果①STEMI和UAP/NSTEMI组患者的血清MPO水平较SAP组明显升高,差异有显著性(P<0.01);其中STEMI患者血清MPO水平高于UAP/NSTEMI组(P<0.01);②具有高水平MPO的患者在随后30 d及90 d的心血管事件发生率明显增高。结论①血清炎症标志物MPO可能独立预测近期心血管事件危险性;②降低高MPO水平患者近期心血管事件发生的风险性下降。

Objective Through the determination of concentration of mediators of pro-inflammation （ MPO ） to study the clinic nuance in risk sratification of ACS. Methods 70 ACS （ STEMI, UAP/NSTEMI ） patients and 20 SAP patients were selected. The activity of MPO was detected by spectrophotometer. We determined the risk for subsequent cardiovascular events during 30 days and 3 months of follow-up, then the results were analyzed. Results①The serum level of MPO was higher in STEMI group and UAP/NSTEMI group than that in SAP group （ P 〈 0. 01 ）, compared with UAP/NSTEMI group, the activity of serum MPO was higher （ P 〈 0. 01 ）. ②The risk for subsequent cardiovascular events was increased in patients with higher serum level of MPO during 30 days and 3 months of follow-up. Conclusions ①The serum inflammatory markers （MPO） were convincing in predicting risk stratification of ACS. ②Higher concentration of MPO serum levels means higher risk for subsequent cardiovascular events.